COMISAIR Study Shows that CGM—Not the Insulin Delivery Method—Drives A1C Reduction
In this novel study, investigators examined not only the benefits of continuous glucose monitoring (CGM) augmented insulin therapy, they also looked at the impact of CGM separately in subjects on multiple daily injection (MDI) regimen vs. insulin pump therapy. Results from this year-long study challenged the notion that patients on MDI would not benefit as significantly from CGM use those on an insulin pump. Furthermore, this study presented convincing evidence that CGM – not the insulin delivery method – drives A1C reduction.
Source: Šoupal J, Petruželková L, Flekač M, et al. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. Diabetes Technol Ther. 2016;18(9):532-538.
Related Content
Continuous Glucose Monitoring Initiation Within First Year of Type 1 Diabetes Diagnosis Is Associated With Improved Glycemic Outcomes: 7-Year Follow-Up Study Anagha Champakanath, Halis Kaan Akturk, G...
The efficacy and safety of the Control-IQ hybrid closed-loop system, powered by Dexcom G6, was evaluated in a multi-centered, randomized, and unblinded study. 1 The researchers randomized 168...